Cells (Oct 2022)

High-Dimensional Cytometry Dissects Immunological Fingerprints of Idiopathic Inflammatory Myopathies

  • Christopher Nelke,
  • Marc Pawlitzki,
  • Christina B. Schroeter,
  • Niklas Huntemann,
  • Saskia Räuber,
  • Vera Dobelmann,
  • Corinna Preusse,
  • Andreas Roos,
  • Yves Allenbach,
  • Olivier Benveniste,
  • Heinz Wiendl,
  • Ingrid E. Lundberg,
  • Werner Stenzel,
  • Sven G. Meuth,
  • Tobias Ruck

DOI
https://doi.org/10.3390/cells11203330
Journal volume & issue
Vol. 11, no. 20
p. 3330

Abstract

Read online

Chronic inflammation of skeletal muscle is the common feature of idiopathic inflammatory myopathies (IIM). Given the rarity of the disease and potential difficulty of routinely obtaining target tissue, i.e., standardized skeletal muscle, our understanding of immune signatures of the IIM spectrum remains incomplete. Further insight into the immune topography of IIM is needed to determine specific treatment targets according to clinical and immunological phenotypes. Thus, we used high-dimensional flow cytometry to investigate the immune phenotypes of anti-synthetase syndrome (ASyS), dermatomyositis (DM) and inclusion-body myositis (IBM) patients as representative entities of the IIM spectrum and compared them to healthy controls. We studied the CD8, CD4 and B cell compartments in the blood aiming to provide a contemporary overview of the immune topography of the IIM spectrum. ASyS was characterized by altered CD4 composition and expanded T follicular helper cells supporting B cell-mediated autoimmunity. For DM, unsupervised clustering identified expansion of distinct B cell subtypes highly expressing immunoglobulin G4 (IgG4) and CD38. Lastly, terminally differentiated, cytotoxic CD8 T cells distinguish IBM from other IIM. Interestingly, these terminally differentiated CD8 T cells highly expressed the integrin CD18 mediating cellular adhesion and infiltration. The distinct immune cell topography of IIM might provide the framework for targeted treatment approaches potentially improving therapeutic outcomes.

Keywords